5939
document
Effectiveness of N , N-dimethylglycine in autism and pervasive developmental disorder . N , N-dimethylglycine , a dietary supplement , has been reported to be beneficial in children with autism and pervasive developmental disorder . We examined the effectiveness of dimethylglycine in children with autism and pervasive developmental disorder in a double-blind , placebo-controlled study . Thirty-seven children between 3 and 11 years of age with a diagnosis of autism and/or pervasive developmental disorder were gender and age matched and randomly assigned to receive either placebo or dimethylglycine for 4 weeks . All children were assessed before and after treatment on two behavioral measures , the Vineland Maladaptive Behavior Domain and the Aberrant Behavior Checklist . Standardized neurologic examinations before and after treatment on 33 children showed no change . An overall improvement on all behavioral measures was observed for both the placebo and the dimethylglycine groups . However , the improvement among the children who received dimethylglycine was not statistically different from the improvement observed among the children who received the placebo . The children who participated in this study were a heterogeneous group , and their apparent responses to the dimethylglycine varied . Some children appeared to respond positively to the dimethylglycine , and there was a smaller proportion of negative changes in the dimethylglycine group , but the quantitative changes in the dimethylglycine behavioral assessments were not significantly different from what was observed among children who received placebo .
5940
Intervention_Pharmacological
N , N-dimethylglycine
5941
Intervention_Control
receive either placebo
5942
Intervention_Pharmacological
dimethylglycine for 4 weeks
5943
Intervention_Educational
two behavioral measures , the Vineland Maladaptive Behavior Domain and the Aberrant Behavior Checklist
5944
Outcome_Other
Effectiveness
5945
Outcome_Mental
Vineland Maladaptive Behavior Domain
5946
Outcome_Mental
Aberrant Behavior Checklist
5947
Outcome_Other
Standardized neurologic examinations before and after treatment
5948
Outcome_Mental
behavioral measures
5949
Participant_Condition
autism and pervasive developmental disorder .
5950
Participant_Condition
children with autism and pervasive developmental disorder .
5951
Participant_Condition
children with autism and pervasive developmental disorder
5952
Participant_Age
Thirty-seven children between 3 and 11 years of age with a diagnosis of autism and/or pervasive developmental disorder